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The investigation of prostatic calcifications using μ-PIXE
-PIXE analysis and their
dosimetric effect in low dose rate brachytherapy treatments using Geant4
Abstract
Low dose rate brachytherapy is a widely used modality for the treatment of prostate cancer. Most clinical
treatment planning systems currently in use approximate all tissue to water, neglecting the existence of
inhomogeneities, such as calcifications. The presence of prostatic calcifications may perturb the dose
due to the higher photoelectric effect cross section in comparison to water. This study quantitatively
evaluates the effect of prostatic calcifications on the dosimetric outcome of brachytherapy treatments by
means of Monte Carlo simulations and its potential clinical consequences. Four pathological calcification
samples were characterised with micro-particle induced x-ray emission (μ-PIXE) to determine their heavy
elemental composition. Calcium, phosphorus and zinc were found to be the predominant heavy elements
in the calcification composition. Four clinical patient brachytherapy treatments were modelled using
Geant4 based Monte Carlo simulations, in terms of the distribution of brachytherapy seeds and
calcifications in the prostate. Dose reductions were observed to be up to 30% locally to the calcification
boundary, calcification size dependent. Single large calcifications and closely placed calculi caused local
dose reductions of between 30–60%. Individual calculi smaller than 0.5 mm in diameter showed minimal
dosimetric impact, however, the effects of small or diffuse calcifications within the prostatic tissue could
not be determined using the methods employed in the study. The simulation study showed a varying
reduction on common dosimetric parameters. D90 showed a reduction of 2–5%, regardless of
calcification surface area and volume. The parameters V100, V150 and V200 were also reduced by as
much as 3% and on average by 1%. These reductions were also found to relate to the surface area and
volume of calcifications, which may have a significant dosimetric impact on brachytherapy treatment,
however, such impacts depend strongly on specific factors in the patient's individual treatment. These
factors include the number, size, composition and spatial distribution of calcifications in the prostate as
well as the distribution of brachytherapy seeds.
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Low Dose Rate (LDR) brachytherapy is a widely used modality for the treatment of prostate cancer. Most
clinical treatment planning systems (TPS) currently in use approximate all tissue to water, neglecting the
existence of inhomogeneities, such as calcifications. The presence of prostatic calcifications may perturb the
dose due to the higher photoelectric effect cross section in comparison to water. This study quantitatively
evaluates the effect of prostatic calcifications on the dosimetric outcome of brachytherapy treatments by
means of Monte Carlo simulations and its potential clinical consequences.
Four pathological calcification samples were characterised with micro-particle induced x-ray emission (μ-PIXE)
to determine their heavy elemental composition. Calcium, phosphorus and zinc were found to be the
predominant heavy elements in the calcification composition. Four clinical patient brachytherapy treatments
were modelled using Geant4 based Monte Carlo simulations, in terms of the distribution of brachytherapy
seeds and calcifications in the prostate. Dose reductions were observed to be up to 30% locally to the
calcification boundary, calcification size dependent. Single large calcifications and closely placed calculi caused
local dose reductions of between 30-60%. Individual calculi smaller than 0.5mm in diameter showed minimal
dosimetric impact, however, the effects of small or diffuse calcifications within the prostatic tissue could not
be determined using the methods employed in the study. The simulation study showed a varying reduction on
common dosimetric parameters. D90 showed a reduction of 2-5%, regardless of calcification surface area and
volume. The parameters V100, V150 and V200 were also reduced by as much as 3% and on average by 1%. These
reductions were also found to relate to the surface area and volume of calcifications, which may have a
significant dosimetric impact on brachytherapy treatment, however, such impacts depend strongly on specific
factors in the patient’s individual treatment. These factors include the number, size, composition and spatial
distribution of calcifications in the prostate as well as the distribution of brachytherapy seeds.
I.INTRODUCTION
Prostatic calculi are small firm objects formed from
calcareous material deposited within the tissue of the
prostate gland [1] and are more commonly found in
older men [2],[3]. Calcifications may be identified using
various imaging modalities, however they are most
easily found during surgical removal of tissues in which
they are contained [4]. Formation of these bodies has
been found to occur in all regions within the prostate,
with substantial variations in degree, frequency and
distribution found amongst individuals [5]. Studies on
whole mount sections of prostatectomy specimens
found that calcifications were present in 88.6% of
specimens in the prostate and ejaculatory system [5].
The development of prostatic calculi has found to be

more common in men with prostate cancer however no
link between the two has been established [6].
Measurements of prostatic calculi samples by means of
Fourier Transform Infrared (FTIR) microspectroscopic
mapping
and
traditional
FTIR
and
Raman
microspectroscopy
determined
that
prostatic
calcifications composition is predominately carbonated
hydroxyapatite [1]; however there was also a significant
amount of calcium oxalate present in a number of the
samples [1]. The Report of Task Group 186 identifies
that there is limited data on the composition of prostatic
calcifications although other studies have suggested that
these may be similar to breast calcifications for which
published data is available [7].

The presence of calcifications in the tumour target is of
concern in Low Dose Rate Brachytherapy (LDR-BT). LDRBT treatments have become frequently used for the
treatment of organ confined or “localised” prostate
cancer [8]. I-125 is a commonly used LDR isotope in
brachytherapy treatments. It has a half-life of 60 days
emitting x-rays with energies of 27.4, 31.4 and 35.5 keV
[9]. Given the low energy output of I-125 radioactive
seeds it is possible that calcifications may have a
significant dosimetric impact. This is due to the
dominance of photoelectric absorption in the keV
ranges and the presence of the high Z elements of which
they are composed [10]. The dosimetric effect of
calcifications can be significant as they attenuate the
photons emitted by the seed more efficiently than the
surrounding prostatic tissue.
The goal of this research was to quantify the effects of
calcifications on the dosimetric parameters of low dose
rate prostate brachytherapy treatments, which are used
to evaluate clinical outcomes inpatient treatments.
Previous studies showed that inaccurate modelling of
LDR-BT in commercial treatment planning systems can
significantly affect the dosimetric outcome of the
treatment [11],[12],[13].
A study evaluating the impact of interseed attenuation
for I-125 permanent seed implants found that variation
in seed density causes reductions in the CTV D90 value of
up to 3% [11]. For studies on the dosimetric impact of
gold fiducial markers in patients receiving combined
external beam and LDR seed treatments, large dose
reductions (up to approximately 50%) were observed at
the distal side of the fiducial markers, while a dose
enhancement was observed at the proximal side [12]. As
a result of these findings [11,12], it is understood that
calcifications may result in comparable dose
perturbations. The dosimetric effect of calcifications in
LDR-BT, using Pd-103 and I-125 seeds has been
quantified by means of Monte Carlo simulations [13].
Calcifications covering 1% to 5% of the prostatic volume
were studied for two patients. For both cases, the value
of D100 was reduced by as much as 25% for a 1% calcified
prostate. When considering a prostate volume
consisting of 5% calcification occupancy, D80, D90, and
D100 were decreased by up to 32%, 37%, and 58%,
respectively [13]. This demonstrates the need to study
the dosimetric impact of calcifications in real patient
LDR-BT treatments
Although
calcification
compositions
such
as
hydroxypapatite [1] have been previously determined,
this study investigates the presence and variance of
heavy elemental components in pathological
calcification samples through micro particle induced xray emission (μ-PIXE) measurements. The dosimetric
effect of these components, both locally and

volumetrically, were determined by modelling clinical
LDR-BT treatment plans, with and without the presence
of calcifications, using a Geant4 Monte Carlo based
application, BrachyPlot. I-125 seed and calcification data
were extracted from clinical treatment plans, allowing
the simulations to determine real clinical effects, not
simply those from arbitrary seed and calcification
positioning. The dose perturbations occurring around
the calcification perimeters, as well as the effect of
these local perturbations on clinical volumetric
parameters, such as D90 V100, V150 and V200, were
studied.

II. MATERIALS AND METHODS
II.A Measurement of pathological calcification
sample compositions
Four pathological calcification samples, obtained from
patients undergoing prostatectomy, with age ranging
from 68 to 79 years, were selected for μ-PIXE
measurements using the Heavy Ion Microprobe (HIMP)
at the Australian Nuclear and Science Technology
Organisation (ANSTO) [14]. As seen in figure 1, each
specimen varied significantly in shape and size.

Fig. 1. Pathological calcification samples of four different
patients. A) Sample 1: 1.93 mm x 0.43 mm x 1.57 mm,
B) Sample 2: 1.19 mm x 0.91 mm x 1.14 mm, C) Sample
3: 2.39 mm x 1.51 mm x 1.56 mm, D) Sample 4: 3.20 mm
x 2.34 mm x 2.50 mm. These were measured using the
largest dimension to fix the x axis and smallest
orthogonal dimension to fix the y axis. Measurements
were performed using callipers.
The HIMP uses a 10 MV Tandem accelerator to
accelerate ions to the MeV energy range. In this
analysis, a 3 MeV proton beam with typical spot size of
between 5 and 10 μm was used. At this spot size, beam
currents between 0.4 and 0.5 nA can be achieved, which
is sufficient for μ-PIXE analyses. A high-purity
2
Germanium (Ge) detector was used with a 100 mm
active area to measure the characteristic X-rays

emerging from the calcification samples. The detector
was located 100 mm from the sample to reduce pile up
due to the high count rate. A 100 μm Mylar foil was
used to reduce low energy X-rays count as well as
prevent scattered protons from entering the detector.
Samples were fixed to the sample holder by means of
double sided carbon tape. This tape is very pure and
does not contain trace elements higher than oxygen
(Z>8). The tape does not affect measurements and is
effective in holding the samples providing good electric
conductivity to allow target current measurement. Each
sample was then scanned for approximately 20 minutes
for extensive emission data to be obtained.
The average elemental concentrations in the samples
were calculated using GeoPIXE [15], [16]. In µ-PIXE,
samples should be very flat, otherwise a shadowing
effect can be observed in the elemental map. This is
clearly visible in sample B of figure 2, which has
separated in the middle. Therefore, only areas of the
maps without shadowing were selected to calculate the
concentration of high Z elements.

Fig. 2. μ-PIXE analysis on each of the four calcification
samples (A): Sample 1 (B): Sample 2 (C): Sample 3 (D);
Sample 4. The map for calcium content is shown in this
particular case with moderate concentration in blue and
high concentration in red. Green outlines show the
selected regions.

II.B Geant4 LDR-BT dosimetric system BrachyPlot
The BrachyPlot application, developed at the Centre for
Medical Radiation Physics, University of Wollongong, is a
Monte Carlo simulation based on the GEANT4 Toolkit
[17][18], and was designed to perform dosimetric
studies addressed to clinical LDR-BT. The virtual
treatment volume within BrachyPlot is modelled with a
3
20 × 20 × 20 cm cubic water phantom, where Oncura
model 6711 I-125 brachytherapy seeds can be placed in
the desired arrangement, recreating a treatment plan. In
terms of geometry and materials, the Oncura model
6711 I-125 brachytherapy seed was modelled in the
simulation [19].
The radiation field consists of photons with I-125
emission energy spectrum, emitted from a random
position located 1m underneath the surface of the
silver core, representing the I-125 implantation, with the
emissions occurring in a random direction. The physical
interactions included in the Geant4 application were
modelled by means of the Livermore Low Energy
Electromagnetic Package [20]. The threshold of
production of secondary particles was fixed to a range of

1m. The interactions modelled were the photoelectric
effect, Compton scattering and Rayleigh scattering for
photons, and Bremsstrahlung, ionisation and multiple
scattering for electrons. Fluorescence emissions from
atomic relaxation was also modelled. Auger electrons
were neglected as their kinetic energy was less than or
approximately equal to the energy cut, (1.5 keV) [21]
corresponding to adopted a 1 μm range cut in this study.
BrachyPlot does not use voxelised geometry within the
Geant4 volume construction routines, however, the
coordinates of all energy depositions within the
sensitive water phantom were mapped to a threedimensional scoring matrix. The sensitive volume, where
3
the energy deposition was calculated, is a 7 × 7 × 7 cm
3D mesh, centred within the water phantom, with 0.1 ×
3
0.1 × 2 mm voxels. This represents 15, 2mm thick
imaging slices, with 5mm pitch, each providing a 2D
dosimetric image with 700 x 700 pixels. Dose maps
were calculated in axial plans that cover the prostate
region. Dose deposition was only scored within the
water phantom, not within any calcification volume or
within I-125 brachytherapy seeds. Dose deposition was
scored from both the energy liberated through
interactions and from the non-transport of secondary
particles created with energies below the transport
threshold (equivalent to 1m range).

II.B Validation of BrachyPlot
BrachyPlot was validated with respect to the dosimetric
protocol prepared by the AAPM Task Group 43 (TG43U1) [22]. A single Oncura 6711 seed was modelled at the
3
centre of a 30 x 30 x 30 cm liquid water phantom. 10
concentric scoring shells of thickness 0.05 mm were
modelled around the seed, with radii from 5mm to 50
mm, in 5 mm increments. The secondary particle
threshold and physical interactions were set to match
that of BrachyPlot. Energy deposited within a scoring
shell was stored in a two dimensional array for radial
distance from the source and angle about the source
axis, with the radial distance equal to the radii of the
shell and the angle rounded to the nearest 5°, as
demonstrated in figure 3. From the dose scoring array,
the TG43 radial dose function values were calculated
and compared to values published in the TG43-U1
report [22]. This allowed the verification of the
suitability of the physics packages used in the BrachyPlot
simulations for LDR-BT Monte Carlo modelling.

Fig. 3. Geant4 simulation validation scoring geometry

II.C Modelling real patient treatments in
BrachyPlot using hydroxyapatite calcification
compositions
BrachyPlot was used to calculate the dose in four
patients deriving from real LDR sources distribution,
with and without calcifications, with a maximum
10
statistical uncertainty of 2%, obtained with 4·10 events
per patient treatment. The 3D dose distribution
calculated by means of BrachyPlot was used to calculate
the clinical parameters D90, V100, V150 and V200. These
parameters indicate the effect of patient’s individual
calcifications over the entire prostate volume and are an
indication of the dose coverage of the prostate for the
LDR brachytherapy treatment. Geant4 version 9.4 was
used for all simulations in the study. ROOT [23] was used
as an analysis tool.
Four clinical LDR-BT treatment plans were studied in this
research. The number of brachytherapy seeds used in
the four patient plans varied as 88, 102, 82 and 83. The
activities of the seeds were 0.508 U in all cases, except
for patient 1, which was 0.4064 U.
The position of the seeds (using CT images) and the size
and position of the calcifications (using ultrasound
images) were retrieved for each patient, in order to
model the treatment configuration in the BrachyPlot
simulation. The CT data was comprised of approximately
12 to 16 images taken throughout the prostate region in
0.5 cm transverse plane (z–plane) slices. x and y
coordinates for each seed were manually obtained by
visually identifying the centroid of each seed on a
DICOM image viewer (ImageJ) and imported into the
BrachyPlot simulation, along with the corresponding z
coordinate of the plane. The Ultrasound images were
originally co-registered to the CT data for clinical
planning and treatment.
Ultrasound imaging is essential for the location of the
calcification formations due to its ability to identify
regions of changing medium. The position and size of
each contoured calcification were obtained directly from
each patient slice. Like the CT image slices, each z-plane
ultrasound slice is spaced by 0.5 cm. As with CT data,
there are multiple ultrasound slices for each patient;
however it was found that formations are usually only

found on three to five slices in most cases. Due to the
complex nature of calcification formations, large single
calcifications were modelled as spheres while clusters
were approximated as a group of spheres. The diameter
of each calcification was determined from the visible
size of each on the ultrasound images.
Ultrasound image analysis showed that the calcification
formations were typically situated in the periurethral
region. The size and number of stones varied greatly in
the four treatment plans under study. In two instances,
calcification cluster groups consisting of multiple large
(approximately 2mm diameter) stones were found.
These were found centrally inside the prostate.
Commonly smaller (less than 2 mm in diameter) stones
are found to be isolated within the prostate. Each plan is
unique however it appears that smaller stones are more
common and their numbers vary significantly. In the
study it was found that calcification numbers varied
from 5 to 33, while diameters of individual stones varied
from 0.2 to 3 mm. The variation of calcification
formation in the four patient plans is summarised in
Table 1.
Data set

No. of
Calcifications

Patient 1

Calcification
Diameter range
(mm)
0.9 – 3.4

5

Percentage
volume
occupancy (%)
0.055

Patient 2

0.2 – 1.0

33

0.006

Patient 3

1.0 – 3.0

6

0.071

Patient 4

1.0 – 2.2

13

0.062

Table 1. Calcification variation across the four patient
plans in regards to size, number and occupancy of the
prostatic volume.
The calcifications were modelled as a hydroxyapatite
(Ca10(PO4)6(OH)2) composition, as identified in [1],
with the results displayed in section III.C. It should be
noted that this composition differs to that
recommended by TG-186 through the omission of
carbon and nitrogen components as well a differing
weight fractions. Alternatively the calcifications were
modelled with the composition determined by means of
μ-PIXE to determine the dosimetric effect of varying
calcification composition; these results are displayed in
section III.D. These compositions include high z trace
elements which have not been considered in [1] or [7].
In all cases the calcifications were modelled with a
-3
density of 3.16 gcm , which differs from the TG-186
-3
recommended value of 3.06 gcm .
All calcification bodies in the four patient LDR-BT
treatments were modelled in BrachyPlot, however only
those showing significant dosimetric effects were
selected for complete analysis. The selection was based
on calcification size, proximity to I-125 seeds and
location in the prostate.

II.C.1 Study of local dosimetric effects
Four clinical patient LDR-BT plans were simulated in
BrachyPlot with and without calcifications, and
comparisons between the two cases were used to
determine quantitatively the local dosimetric effect
around calcifications of interest. In this section, the
calcification composition was kept fixed to that of
hydroxyapatite for all simulations. Across the four
patient plans, fourteen individual calcifications were
analysed in total, all of which varied in size, formation
and location throughout the prostate. These unique
stones were selected based on the factors as detailed in
section II.C.
Two dimensional dose distributions were obtained in
planes corresponding to slices containing calcifications.
The relative percentage difference (RPD) with and
without calcifications was calculated in the axial planes
containing calcifications of interest. One dimensional
dose distributions were obtained on each slice of
interest horizontally through the location of the
calcifications. Black vertical lines on the resultant plots
indicate the boundary of the calcification. The dose is
not calculated inside the calcification body and
therefore no dose is measured between these lines for
simulations containing calcifications. The displacement
is indicated by the distance on either side of the
boundary at which the dose calculated with and without
calcifications fall within the statistical error affecting the
simulation results. As individual dose values have an
uncertainty of 2%, displacement was defined as the
distance from the calcification boundary to the point at
which both simulation plots are within a 4% uncertainty
limit. The doses from two virtual voxels either side of
each calculi containing both calcification and water were
ignored as the volume of sensitive material (water)
within the voxels was reduced.

II.C.2 Study of LDR-BT volumetric parameters
The impact of calcifications on the clinical dosimetric
parameters for LDR brachytherapy treatments were
studied for the same four patient plans. Parameters D90,
V100, V150 and V200 were determined based on the
simulation results obtained by means of BrachyPlot. The
parameter D90 is the minimum dose received by 90% of
the clinical target volume (CTV), while parameters V100,
V150 and V200 indicate the percentage of the CTV that
receives at least 100%, 150% and 200% of the
prescription dose respectively [24].
The total surface area and volume for all calcifications
present in the patient plans were calculated and their
impact on the clinical dosimetric parameters for LDR
brachytherapy treatments studied. Since the exact
Clinical Target Volume (CTV) could not be determined,
and to eliminate discrepancies directly due to human

error during voluming, the 100% isodose (corresponding
to a dose equal to 144 Gy or higher) surface was used to
determine the CTV in simulations without calcifications.
The same CTV was used in the simulations with the
calcifications modelled. To determine the parameter D90
for simulations both with and without calcifications, the
doses in all voxels within the CTV were extracted, and
sorted from highest to lowest. The 90th percentile of
the collection was specified as D90. For each simulation,
V100, V150 and V200 were calculated by summing volume
of the voxels that represented a treatment dose of 144
Gy, 216 Gy and 288 Gy respectively.

II.D Modelling real patient treatments in
BrachyPlot using varied calcification compositions
from μ-PIXE measurements.
In this section, the dosimetric impact of different
calcification compositions are analysed. The composition
of calcifications derived from μ-PIXE (see Table 2), are
used to model the calcifications in the LDR-BT treatment
plan of patient 3 in BrachyPlot. Patient 3 was chosen for
this study as it displayed a number of calcifications with
unique size and location in comparison to the other
three plans. Using the four μ-PIXE derived calcification
compositions, simulation data was obtained and
analysed using the same process as the hydroxyapatite
simulations. Since a single plan was used, each
simulation contained exactly the same calcification and
therefore four comparative simulations were obtained.
As this plan contained less calcification bodies, analysis
was only taken across five complimentary stones for
each simulation.

III. RESULTS AND DISCUSSION
III.A Pathological sample compositions
Results from the Heavy ion microprobe found the
following components were present in most of the
samples: phosphorus (P), sulphur (S), chlorine (Cl),
potassium (K), calcium (Ca), iron (Fe), zinc (Zn), and
strontium (Sr). Bromine (Br) was also detected but in
such low concentrations (order of parts per million) that
the contribution of this element was considered
insignificant.
The specific concentrations of the elements contained in
each sample are provided in Table 2.
Element

Sample 1
(%)

Sample
2 (%)

Sample
3 (%)

Sample
4 (%)

Phosphorus

23.08 ±
4.62

24.89 ±
4.98

1.05 ±
0.21

14.96 ±
2.99

Sulphur

0.29 ±
0.06

0.34 ±
0.07

2.68 ±
0.54

3.17 ±
064

Chlorine

0.44 ±

0.24 ±

0.70 ±

0.11 ±

0.09

0.05

0.14

0.02

Potassium

0.06 ±
0.01

0.84 ±
0.17

0.26 ±
0.05

0.60 ±
0.12

Calcium

39.55 ±
7.91

35.56 ±
7.11

27.07 ±
5.41

30.08 ±
6.02

Iron

0.007 ±
0.001

N/A

0.012 ±
0.002

0.06 ±
0.01

Zinc

7.74 ±
1.55

3.04 ±
0.07

0.46 ±
0.09

4.99 ±
1.0

Strontium

0.035 ±
0.007

0.026 ±
0.005

N/A

0.032 ±
0.006

Undetectable
Components

~28.78

~35.07

~67.77

~46.02

Table 2. Elemental concentration percentages measured
in each calcification sample using μ-PIXE measurements.
The results showed that most of the samples have a
similar formation. Although variations occur in each
case, the samples display a similar pattern with higher
concentrations of calcium, phosphorus and zinc. Figure 4
shows the concentration maps for these three elements
in the case of sample 1. The only major discrepancy
amongst the samples was a low phosphorus
concentration measured in sample 3. As the overall
percentage of high z elements is low in this sample, it is
likely that this stone may contain a high concentration of
lighter elements not detected by μ-PIXE. There are a
number of possible discrepancies in the measurement of
elemental concentrations which may account for
relative variations in the sample results. As the
calcification body is not a flat surface, characteristic xrays generated from within a cavity or on the posterior
side of the calcification will be attenuated and therefore
a loss of data will occur.

Fig. 4. Phosphorus (P), Calcium (Ca) and Zinc (Zn)
elemental maps for the calcification stone obtained
from sample 1. The axis on the right represents the
percentage of detected x-ray emissions from the specific
element over the entire sample.
The variations in sample concentrations may be due to
the synthesis process. If synthesis occurs in a different
manner in each patient, it might explain why relative
variations are observed, however this problem goes
beyond the scope of this paper. It is difficult to obtain a
total understanding of the concentrations found in a
wide variety of patients when four samples only were

analysed, however these measurements are important
as it is the first time μ-PIXE has been used to study the
composition of prostatic calcifications. Future
examination of other samples would be useful to
increase statistics and gain a more comprehensive
understanding of the composition of calcifications.
As μ-PIXE is not capable of detecting lighter elements
such as hydrogen, carbon and oxygen which are
fundamental components of known calcifications
compositions [1], a complete composition analysis is not
possible using this technique alone. Particle induced
gamma emission (PIGE) techniques can determine low Z
components however this was not available at the
facility and therefore could not be utilised for this study.
As lighter elements could not be detected by μ-PIXE as
described, it has been assumed that the missing
undetectable concentration percentages can be
approximated by oxygen for calcification modelling in
simulation studies. This is consistent with the previously
mentioned literature showing hydroxyapatite and
calcium oxalate being major components comprising
calcifications.

III.B BrachyPlot validation
Figure 5 shows the radial dose function obtained by
means of a Geant4 simulation by TG43 published values.
The Geant4 simulation agrees with TG43 within 5% for
distances within 50 mm from the source. This
agreement of radial dose function with depth indicates
the energy spectrum emitted from the seed, as well as
the physical interaction models used in the simulation
are adequate for the study.

Fig. 5. Radial dose function for the Oncura 6711 seed, as
generated using Geant4 and published in the TG43
reference data.

III.C Hydroxyapatite calcification composition
simulation results
III.C.1 Calcification local dosimetric effect
As seen in figure 6, the calcification is located in close
proximity to an LDR brachytherapy seed and indicates a
reduction predominately to the posterior side of the
boundary with respect to the I-125 seed, as shown in

figure 7. The reduction on the left side of the boundary
starts at approximately 26% and takes a distance of 2.2
mm from the calcification boundary to be statistically
insignificant. The dose on the right hand side (in front of
the I-125 seed), however, shows that the initial dose at
the boundary reduction is approximately 7% which
becomes statistically insignificant at a distance of 0.4
mm from the calcification boundary.

Fig. 8. Comparative dose effect in the 2 cm z-plane due
to calcification presence in patient 3 (1 pixel = 0.1 x 0.1
2
mm ).

Fig. 6. Comparative dose effect in the 2 cm z-plane due
to calcification presence in patient 1 (1 pixel = 0.1 x 0.1
2
mm ).

Fig. 9. Dose along the x-axis passing through the centre
of the calcification cluster (both 3mm in diameter)
shown in Fig. 8.

Fig. 7. Dose along the x-axis passing through the centre
of the 2 mm diameter stone shown in Fig. 6.
Figures 8 and 9 show the results obtained for a
calcification cluster in patient 3, close to the position of
a LDR treatment seed. This calcification, presents a dose
reduction of approximately 22% on the posterior side of
the calcification boundary. This dose reduction becomes
statistically insignificant at a distance of 3.6 mm from
the calcification. It was once again found that there is a
small reduction on the anterior side of the calcification
(closest to the I-125 seed). This was slightly greater than
4% and became insignificant at 1 mm from the
boundary. The major difference in this case is the high
dose reduction in the central region, between the two
calcifications composing the cluster. In this 0.5 mm
region the average reduction observed was 50%.

Figures 10 and 11 provide an example of dosimetric
effect due to a large 2.4 mm diameter calcification
found in patient 4, detected on the 1.5 cm axial prostate
plane. As can be observed in figure 11, this calcification
creates a gradual reduction either side of its boundary.
On the left hand side of the plot, initial boundary
reductions start at approximately 24% and become
insignificant at 2 mm from the calcification boundary.
The initial reduction to the right side of the plot is
slightly lower at 17% and only takes 0.6 mm to become
statistically irrelevant.

Fig. 10. Comparative dose effect in the 1.5 cm z-plane
due to calcification presence in patient 4 (1 pixel = 0.1 x
2
0.1 mm ).

Fig. 11. Dose along the x-axis passing through the centre
of the 2.4 mm diameter stone shown in Fig. 10.
In patient 2, a number of small calcifications with a
diameter of less than 0.5 mm were detected, as shown
in figure 12. Upon quantitative analysis, it was
determined that these small individual calcifications
provided very little dosimetric perturbation. Limitations
in the identification of small calcifications using
ultrasound, including the size and number of
calcifications of diameter below 0.5 mm, restrict the
inclusion of the effects of small and diffuse calcifications
within the prostatic tissue in the study, therefor these
effects should not be ignored.

and 4 mm from the calcification boundary in all cases,
however these values are strongly dependent on
calcification size and proximity to brachytherapy seeds.
A significant dose reduction (greater than 7%) at the
boundary of calcifications with diameter bigger than 0.5
mm is always observed independently of their relative
position with respect to the brachytherapy seeds.
Another significant finding of these simulations is the
shadow effect caused by calcification and seed
alignment (i.e. Fig. 6 and 7). In this configuration, dose
reductions between 10-30% are observed behind the
calcification as in other cases, however the distance
from the calcification boundary where the dose
reduction becomes negligible is increased by at least 1
mm.

III.C.2 Impact of calcifications
volumetric parameters

on

LDR-BT

Table 3 shows the LDR-BT clinical parameters
determined by means of the BrachyPlot simulations,
modelling the treatments of four real patients. The
composition of the calcification is hydroxyapatite.
Calculi
Surface
area
(cm2)
0.66
cm2

Calculi
Volume
(cm3)

D90

V100

V150

V200

0.029
cm3

-2.83
±0.47

-1.21
±0.21

-1.26
±0.33

-0.51
±0.38

2

0.26
cm2

0.003
cm3

-2.39
±1.72

-0.46
±0.42

-0.42
±0.21

-0.12
±0.41

3

0.90
cm2

0.038
cm3

-2.36
±0.25

-1.02
±0.14

-2.50
±0.10

-1.02
±1.20

4

1.07
cm2

0.033
cm3

-2.27
±1.13

-1.13
±0.16

-1.00
±0.32

-0.51
±0.30

Patient
simulation

1

Fig. 12. Comparative dose effect in the 1 cm z-plane due
to calcification presence in patient 2 (1 pixel = 0.1 x
2
0.1mm ).

Table 3. The reduction percentages caused to the clinical
parameters by hydroxyapatite calcification inclusion in
the prostatic volume. The errors are obtained from the
combination of the standard deviation of 20 simulations,
of 2 billion histories each.

From the analysis of all identified calcifications, the
results found substantial local dose reductions at the
boundary of calcifications when their diameter is larger
than approximately 0.5 mm. The amount of dose
reduction depends strongly on the brachytherapy seeds
location and on the size of the calcification. Calcification
formations with diameter between 1 and 2 mm show
dose reductions on the boundary between 7 and 30%.
Calcifications larger than 2 mm in diameter show dose
reductions in a similar range, however, reductions of 2030% are observed more often. The most significant dose
reductions are those found between two large stones in
a cluster formation (figures 8 and 9). These reductions
were found to be between 33-62%. Dose reductions
were observed up to distances ranging between 0.5 mm

The results showed a reduction of approximately 2% to
3% for D90, independently from the total calcification
area and volume. Reductions were also found in V 100,
V150 and V200 although these were much lower with
reductions no greater than 2.5% in all cases. V200 was
quite low for all patients and this is likely to be
determined by the distance of calcifications from the
brachytherapy seeds. It was observed that the
parameters V100, V150 and V200 of Patient 2 had
reductions two times smaller than the other three
patient cases. This appeared to be determined by the
small total surface area and volume of this patient’s
calcifications. Patient 3 is characterised by a higher

reduction in V150 and V200 and this should be due to the
presence of a large calcification in very close proximity
with a brachytherapy seed. From the analysis of the
dosimetric parameters, the dose reductions calculated
in all patients were not clinically significant as they are
smaller than a few percent. It is important to note that
calcification have a very significant local dosimetric
effect which is not evaluated in the determination of the
dosimetric parameters.

III.D Varied Calcification Composition Simulation
Results
III.D.1 Local dosimetric effect
The effect of varied calcification composition, based on
μ-PIXE results, was assessed for a number of stones in
the plan of patient 3. In this section, greater statistics
were generated to give less uncertainty between the
varied composition simulations. The convergence was
determined at the point at which the calcification and
no calcification data were within statistical error. For
moderate isolated stones (approximately 1.5 - 2mm in
diameter), it was found that variations in the
calcification composition reduced the dose delivered
locally to the calcification boundary between
approximately 10 to 20%. The local dose was affected up
to approximately 2mm from the calcification boundary
with convergence distances between compositions only
varying by less than half a millimetre. Figure 13 shows
the dose along the x-axis through a 1.7 mm diameter
stone for the different calcification compositions used.

2

-16.3 ±
2.5

1.3

-13.0 ±
2.5

1.3

3

-9.3 ±
2.5

1.2

-15.3 ±
2.5

1.4

4

-11.5 ±
2.5

1.3

-16.1 ±
2.5

1.2

Table 4. Initial dose reductions and convergence
distance on the left and right boundary of the 1.7mm
diameter).
In the case of the calcification cluster (seen in figure 8),
varying the calcification composition produced
reductions in the dose locally to the boundary on the
anterior and posterior side in regards to the nearby
brachytherapy seed. On the anterior side of the
calcification boundary, dose reductions were between 3
- 6%, with the dosimetric effect becoming negligible
within 2mm for all compositions. On the posterior side
of the calcification boundary reductions were between
22 - 26% and the dosimetric effect became negligible
between 3.5 - 4.5 mm. In the region between the two
calcifications, dose reductions achieved values between
50 - 60%. As previously determined, the study showed
that the boundary dose reductions depend strongly on
calcification size and proximity to LDR seeds. It was
found that there was a very limited dependency of the
dose reductions in respect to the different calcification
compositions studied in this section. Table 5 shows the
range of reductions measured using the varied
calcification compositions in patient 3.
Diameter of
calcifications
analysed
(mm)

Left
boundary
reduction
range (%)

convergence
distance
range: Left
(mm)

Right
boundary
reduction
range (%)

Convergence
distance
range: right
(mm)

2 x 3 mm
(Cluster)

22.4 25.8

3.5 – 4.5

2.9 - 4.5

1.5 - 1.8

2mm

17.3 21.9

1.3 - 2.2

11.2 18.7

1.3 - 1.5

1.8mm

7.6 14.2

0.8 - 1.7

15.1 26.2

0.5 – 1.5

Table 5. Dose reduction and convergence ranges for
varied calcification size and compositions.
Fig. 13. Dose along the x-axis passing through the centre
of a 1.7mm diameter stone in patient 3 (for 4 different
calcification compositions).

Composition

Left
boundary
reduction
(%)

convergence
distance:
Left (mm)

Right
boundary
reduction
(%)

Convergence
distance:
right (mm)

1

-13.9 ±
2.5

1.5

-18.7 ±
2.5

1.4

The dose reductions are of the same magnitude of those
found with the fixed hydroxyapatite composition,
however slightly larger in most cases. This is determined
by the greater presence of high Z elements in the
calcification compositions measured by μ-PIXE. With
respect to composition 1, 2 and 4, composition 3 was
characterised by smaller dose reductions in a number of
cases, determined by the higher concentration of
oxygen (Z=8) and therefore by a reduced probability of
photoelectric absorption. The results obtained with

composition 3 were closer on average to the results of
the fixed hydroxyapatite composition used on the same
patient plan. When changing the composition of
calcifications, it was found that all simulations varied by
less than 11%.

III.D.2 Effect of calcification composition on LDRBT clinical dosimetric parameters
The dosimetric effect on the parameters for LDR
brachytherapy treatment were analysed for the four μPIXE simulations in the same manner as the fixed
hydroxyapatite composition simulations.
The impact of composition in the fixed plan of patient 3
gave reductions to D90, V100, V150 and V200 as shown in
Table 6. The surface area and total volume of the
2
3
calcifications are 0.90 cm and 0.04 cm , respectively.
Patient 3
composition

D90

V100

V150

V200

μ-PIXE sample
1

-4.13
±0.15

-0.72
±0.09

-5.24
±0.09

-2.41
±0.79

μ-PIXE sample
2

-3.65
±0.16

-0.46
±0.11

-.5.46
±0.08

+2.56
±0.58

μ-PIXE sample
3

-3.62
±0.13

-0.41
±0.08

-5.39
±0.08

-2.61
±0.70

μ-PIXE sample
4

-2.86
±0.13

0.76
±0.09

-3.08
±0.08

-1.62
±0.80

Table 6. Reduction percentages caused to the clinical
parameters by the inclusion of varied calcification
compositions in the prostatic volume for patient 3. The
errors are obtained from the combination of the
standard deviation of 50 simulations, of 2 billion
histories each.
The results of these simulations show that the
reductions caused to D90 (between 2.8-4.2%) are higher
in comparison to those found with the fixed
hydroxyapatite composition for patient 3. For V100
reductions were found to be similar to the
hydroxyapatite composition while V150 and V200 were
approximately 2 times greater. From the findings there
appears to be no significant trend that shows that
varying composition (based on μ-PiXE measurements)
has a distinct effect in each of the four cases. Based on
the obtained results it is difficult to assess the impact of
varied composition. It does however appear that the
addition of heavy elements included in the calcification
structure has increased the reductions to some of the
dosimetric parameters in comparison to those
presented in section III.C.
IV. CONCLUSION
Brachytherapy is a widely used radiotherapy treatment
in Australia and in the world to cure prostatic cancer.

Commercial treatment planning systems (TPS) currently
used in radiotherapy approximate all materials to water
without considering the existence of prostatic
calcifications. This research consisted in the evaluation
of the dosimetric effect of prostatic calcifications in real
clinical brachytherapy treatments. The morphology of
four pathological calcification samples was studied. The
size of a stone can vary from submillimeter size to 3 mm
in diameter, the number of stones in a single patient
varied between two to over 80. The shape of the
calcifications can be either spherical or present
irregularities. More pathological calcifications should be
examined in future studies to increase the statistics.
One section of the study consisted in measuring the
elemental concentrations in four pathological
calcification samples by means of μ-PIXE analysis, at
ANSTO. This study showed that the higher contributing
heavy elements in the calcification composition are
calcium, phosphorous, zinc. Oxygen was not detected
however this is assumed to be one of the most
abundant elements as the concentration ratios suggest a
hydroxyapatite composition. From the measurements,
the calcification compositions were found to vary
significantly among different patients.
A Geant4 simulation was developed to study the
dosimetric effect of calcifications in four real clinical
treatments. The position of the brachytherapy seeds
and of the calcifications was retrieved by Computed
Tomography and ultrasound images. The calcifications
were modelled in the simulations as spheres with
dimensions as determined from patients’ treatment
imaging. This study showed that the presence of
calcifications reduce the dose locally. The dose
reduction depends on the size and proximity of the
stones to the brachytherapy seeds. The average of dose
reduction at the boundary was approximately 20% and
reaching a maximum, extreme value of 60% at the
calcification boundary. On average it was found that
larger stones produce a higher local dose reduction. On
average dose reductions were observed up to a few
millimetres from the calcification boundary, however
severity was dependent strongly on relative location of
the stone with respect to the brachytherapy seeds.
Although stones with diameters of less than 0.5 mm
provided limited results in this work, the dosimetric
perturbations caused by these small calcifications should
not be discounted. Future studies will be useful in
determining the dosimetric impact of these extremely
small calcifications. This will involve performing
simulations with calcification input based on the
variation of Hounsfield units within the patient CT, as
opposed to the identification of calcifications on
ultrasound. This method will not only assist in the
inclusion of diffuse calcifications within the prostatic
tissue into the simulation, but will provide model based

determinations of the effects of calcifications on
brachytherapy dosimetry, in line with the TG-186
recommendations [7]. Dosimetric parameters used in
prostate brachytherapy treatments, D90, V100, V150 and
V200, were calculated for the four treatment plans, using
a fixed hydroxyapatite composition as well as a fixed
patient plan using four compositions determined by μPIXE.
It was found that D90 was reduced in all cases between
2-4.2% regardless of calcification total surface area,
volume and composition. Reductions of this magnitude
are equivalent to those caused by interseed attenuation
effects as studied by Carrier et al. [11]. In contrast, the
studies of Chibani et al. [13] found the parameter D90
was reduced by as much as 37% when considering a 5%
calcified prostate volume. The simulation techniques of
Chibani et al. [13] vary greatly to those presented in this
study. The code developed by Chibani et al. [13]
randomly distributes calcification voxels over the entire
prostate volume and therefore does not form a singular
calcified body. It is also found that calcification
occupancy of 5% is two times greater than those
adopted in this study based on clinical patient data.
Discrepancies between the two studies may be due to
the specification of the CTV used for the determination
of the dosimetric parameters. Given the different
configuration of the study, it is difficult to draw any
conclusion from the comparison with the work of
Chibani et al. [13].
The parameters V100, V150 and V200 were affected by
calcification surface area and volume; however the
effect in most cases is no more than 5.5%.
The reductions caused to the clinical dosimetric
parameters in this study are not considered clinically
significant; however the observed local dose reductions,
not considered in these parameters, may affect the
clinical outcome of LDR prostate cancer treatments.
Therefore this work shows that the use of dosimetric
parameters may not be sufficient to characterise the
effect of calcifications. More research in this direction
will be of great benefit to the studies of the dosimetric
effects of prostatic calcifications on clinical LDR
brachytherapy treatments. There are some limitations
to this work, in which the impact of diffuse calcifications
has not been considered. In the instances where
calcifications too small for detection in the imaging
modalities are present in the prostatic tissue, the effects
of these on the dose depositions are not accounted for.
Future adaptation of TG 186 planning systems may
assist in improving the dosimetric calculations for low
dose rate prostate brachytherapy in the presence of
prostatic calcifications.
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